Recon: Merck’s combination therapy for lung cancer falters in phase 3 trial; Medicare to cover Wegovy for heart disease

Recon

ReconJason Scott

Biologics/ biosimilars/ vaccinesEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyUnited States